Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19

NCT06383819 is registered in ClinicalTrials.gov with NPO Petrovax as lead sponsor.

NCT NCT06383819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06383819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
Lead sponsor
NPO Petrovax
Phase
Phase 3
Overall status
Completed
Start date
April 8, 2022
Completion date
December 31, 2023
Enrollment
392 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, lung disease with polymyositis, lung diseases, interstitial, lung; disease, interstitial, with fibrosis, post-acute covid-19 syndrome